Clopidogrel versus Aspirin Monotherapy in Patients with High Ischemic Risk after PCI: SMART-CHOICE 3 Trial
The SMART-CHOICE 3 trial demonstrated that in patients at high risk for recurrent ischemic events after PCI, clopidogrel monotherapy following a standard duration of dual antiplatelet therapy (DAPT) significantly reduced the risk of the composite outcome of all-cause death, myocardial infarction (MI), and stroke compared to aspirin monotherapy, without increasing bleeding, according to a study presented by Dr. Joo-Yong Hahn, Samsung Medical Center, South Korea, in the Late-Breaking Clinical Trials session at ACC.25.
- Free Registration
-
Already have an account?Log In
A portal site of complex catheter intervention techniques
TCROSS NEWS Global is an online medical journal that provides
valuable information on Cardiovascular medicine to medical professionals
worldwide.
We bring you the latest findings and trends in all areas of
cardiovascular medicine. Please register and subscribe for unlimited access to
quality Cardiovascular News!
We provide timely and up-to-date information to our partners across the world by covering and reporting live sessions and conferences, featuring of complex cases, newsletters, academic researches and case studies.
Recommendations
